Non-FDG PET/CT

Lopci, Egesta; Fanti, Stefano

doi:10.1007/978-3-030-42618-7_20

Cited by 10 publications

(6 citation statements)

References 293 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the diagnosis and staging of pancreatic cancer, PET/CT (Positron Emission Tomography/Computed Tomography) has a limited value. To date, few PET agents have been developed, with 2-[18F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG) being the most widely used in clinical radiopharmaceutical practice, accounting for more than 90% of worldwide studies with PET [ 24 ]. However, [ 18 F]FDG is ineffective for non-invasive diagnostic imaging of PDAC.…”

Section: Current Status Of Pdac Imagingmentioning

confidence: 99%

Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography

González-Gómez

Pazo‐Cid

Sarria

et al. 2021

JCM

View full text Add to dashboard Cite

Diagnosis of pancreatic ductal adenocarcinoma (PDAC) by current imaging techniques is useful and widely used in the clinic but presents several limitations and challenges, especially in small lesions that frequently cause radiological tumors infra-staging, false-positive diagnosis of metastatic tumor recurrence, and common occult micro-metastatic disease. The revolution in cancer multi-“omics” and bioinformatics has uncovered clinically relevant alterations in PDAC that still need to be integrated into patients’ clinical management, urging the development of non-invasive imaging techniques against principal biomarkers to assess and incorporate this information into the clinical practice. “Immuno-PET” merges the high target selectivity and specificity of antibodies and engineered fragments toward a given tumor cell surface marker with the high spatial resolution, sensitivity, and quantitative capabilities of positron emission tomography (PET) imaging techniques. In this review, we detail and provide examples of the clinical limitations of current imaging techniques for diagnosing PDAC. Furthermore, we define the different components of immuno-PET and summarize the existing applications of this technique in PDAC. The development of novel immuno-PET methods will make it possible to conduct the non-invasive diagnosis and monitoring of patients over time using in vivo, integrated, quantifiable, 3D, whole body immunohistochemistry working like a “virtual biopsy”.

show abstract

Section: Current Status Of Pdac Imagingmentioning

confidence: 99%

Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography

González-Gómez

Pazo‐Cid

Sarria

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Thus, the PET tracers generally consist of radionuclide-labeled forms of the “building blocks” of macromolecules: sugars, amino acids, and nucleotide bases [ 27 ]. The gold standard tracer for most PET cancer imaging is 2-[ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG), a fluorine-18 glucose analog [ 30 ], being the most widely used in clinical radiopharmaceutical practice, and accounting for more than 90% of total PET scans [ 31 ]. There are several tracers based on neutral amino acid analogues, such as [ 11 C]methionine ([ 11 C]MET), [ 18 F]fluoroethyl-tyrosine ([ 18 F]FET), [ 18 F]L-fluoro-dihydroxyphenylalanine ([ 18 F]FDOPA), or [ 18 F]fluoro-thymidine ([ 18 F]FLT), that show high diagnostic performance [ 27 , 32 ].…”

Section: Neuroimagingmentioning

confidence: 99%

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Ruiz-López

Calatayud-Pérez

Castells-Yus

et al. 2021

Cancers

View full text Add to dashboard Cite

Neuroimaging has transformed neuro-oncology and the way that glioblastoma is diagnosed and treated. Magnetic Resonance Imaging (MRI) is the most widely used non-invasive technique in the primary diagnosis of glioblastoma. Although MRI provides very powerful anatomical information, it has proven to be of limited value for diagnosing glioblastomas in some situations. The final diagnosis requires a brain biopsy that may not depict the high intratumoral heterogeneity present in this tumor type. The revolution in “cancer-omics” is transforming the molecular classification of gliomas. However, many of the clinically relevant alterations revealed by these studies have not yet been integrated into the clinical management of patients, in part due to the lack of non-invasive biomarker-based imaging tools. An innovative option for biomarker identification in vivo is termed “immunotargeted imaging”. By merging the high target specificity of antibodies with the high spatial resolution, sensitivity, and quantitative capabilities of positron emission tomography (PET), “Immuno-PET” allows us to conduct the non-invasive diagnosis and monitoring of patients over time using antibody-based probes as an in vivo, integrated, quantifiable, 3D, full-body “immunohistochemistry” in patients. This review provides the state of the art of immuno-PET applications and future perspectives on this imaging approach for glioblastoma.

show abstract

“…This is the case, for instance, of early-stage prostate cancer and some types of gastric cancers (17,18). This and a better understanding of biological mechanisms underlying metabolic and pathogenic pathways coupled with progress in radiochemistry have stimulated the development of novel PET radiopharmaceuticals (19)(20)(21)(22)(23)(24)(25). Initially, PET radiotracers were small endogenous molecules in which one atom was replaced with an equivalent or similar positronemitting atom ( 11 C, 13 N, 18 F, and 124 I), thus minimally altering their in vivo behavior.…”

Section: Introductionmentioning

confidence: 99%

Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Lepareur

2022

Front. Med.

View full text Add to dashboard Cite

Over the last couple of decades, gallium-68 (68Ga) has gained a formidable interest for PET molecular imaging of various conditions, from cancer to infection, through cardiac pathologies or neuropathies. It has gained routine use, with successful radiopharmaceuticals such as somatostatin analogs ([68Ga]Ga-DOTATOC and [68Ga]GaDOTATATE) for neuroendocrine tumors, and PSMA ligands for prostate cancer. It represents a major clinical impact, particularly in the context of theranostics, coupled with their 177Lu-labeled counterparts. Beside those, a bunch of new 68Ga-labeled molecules are in the preclinical and clinical pipelines, with some of them showing great promise for patient care. Increasing clinical demand and regulatory issues have led to the development of automated procedures for the production of 68Ga radiopharmaceuticals. However, the widespread use of these radiopharmaceuticals may rely on simple and efficient radiolabeling methods, undemanding in terms of equipment and infrastructure. To make them technically and economically accessible to the medical community and its patients, it appears mandatory to develop a procedure similar to the well-established kit-based 99mTc chemistry. Already available commercial kits for the production of 68Ga radiopharmaceuticals have demonstrated the feasibility of using such an approach, thus paving the way for more kit-based 68Ga radiopharmaceuticals to be developed. This article discusses the development of 68Ga cold kit radiopharmacy, including technical issues, and regulatory aspects.

show abstract

Non-FDG PET/CT

Cited by 10 publications

References 293 publications

Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography

Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Contact Info

Product

Resources

About